These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29305821)

  • 21. Protocol for a within-trial economic evaluation of a psychoeducational intervention tailored to people at high risk of developing a second or subsequent melanoma.
    Dieng M; Cust AE; Kasparian NA; Butow P; Costa DS; Menzies SW; Mann GJ; Morton RL
    BMJ Open; 2016 Oct; 6(10):e012153. PubMed ID: 27855094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Projected Return on Investment From Implementation of a Lifestyle Intervention to Reduce Adverse Pregnancy Outcomes.
    Lloyd M; Teede H; Bailey C; Callander E; Ademi Z
    JAMA Netw Open; 2022 Sep; 5(9):e2230683. PubMed ID: 36066890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of skin cancer screening for individuals age 14 to 34 years.
    Schmitt J; Seidler A; Heinisch G; Sebastian G
    J Dtsch Dermatol Ges; 2011 Aug; 9(8):608-16. PubMed ID: 21501381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review.
    Gordon LG; Rowell D
    Eur J Cancer Prev; 2015 Mar; 24(2):141-9. PubMed ID: 25089375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    Arrospide A; Rue M; van Ravesteyn NT; Comas M; Soto-Gordoa M; Sarriugarte G; Mar J
    BMC Cancer; 2016 Jun; 16():344. PubMed ID: 27251556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and cost-effectiveness of hospice care for metastatic melanoma patients.
    Huo J; Lairson DR; Du XL; Chan W; Buchholz TA; Guadagnolo BA
    Am J Manag Care; 2014 May; 20(5):366-73. PubMed ID: 25181566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An estimate of the cost of treating non-melanoma skin cancer in the state of São Paulo, Brazil.
    Souza RJ; Mattedi AP; Corrêa MP; Rezende ML; Ferreira AC
    An Bras Dermatol; 2011; 86(4):657-62. PubMed ID: 21987129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An estimate of the potential budget impact of using prophylactic dressings to prevent hospital-acquired PUs in Australia.
    Santamaria N; Santamaria H
    J Wound Care; 2014 Nov; 23(11):583-4, 586, 588-9. PubMed ID: 25375406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-melanoma skin cancer in Australia.
    Fransen M; Karahalios A; Sharma N; English DR; Giles GG; Sinclair RD
    Med J Aust; 2012 Nov; 197(10):565-8. PubMed ID: 23163687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excess hospital costs incurred by individuals with child abuse and neglect history in South Australia: A birth-cohort study.
    Gnanamanickam ES; Brown DS; Armfield JM; Segal L
    Prev Med; 2023 Jan; 166():107378. PubMed ID: 36493867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of reduced follow-up in malignant melanoma.
    Hengge UR; Wallerand A; Stutzki A; Kockel N
    J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of a melanoma screening programme using whole disease modelling.
    Buja A; Rivera M; Girardi G; Vecchiato A; Rebba V; Pizzo E; Sileni VC; Palozzo AC; Montesco M; Zorzi M; Sartor G; Scioni M; Bolzan M; Fiore PD; Bonavina MG; Rugge M; Baldo V; Rossi CR
    J Med Screen; 2020 Sep; 27(3):157-167. PubMed ID: 31711359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Underutilization of Routine Ultrasound Surveillance after Endovascular Aortic Aneurysm Repair.
    Mell MW; Garg T; Baker LC
    Ann Vasc Surg; 2017 Oct; 44():54-58. PubMed ID: 28501663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs and savings associated with community water fluoridation programs in Colorado.
    O'Connell JM; Brunson D; Anselmo T; Sullivan PW
    Prev Chronic Dis; 2005 Nov; 2 Spec no(Spec No):A06. PubMed ID: 16263039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs of interventions for visual impairment.
    Taylor HR; Pezzullo ML; Nesbitt SJ; Keeffe JE
    Am J Ophthalmol; 2007 Apr; 143(4):561-5. PubMed ID: 17222383
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.